60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Neutral Rating from HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

SXTP traded down $0.03 on Friday, hitting $0.92. 37,163 shares of the company were exchanged, compared to its average volume of 246,209. 60 Degrees Pharmaceuticals has a 12 month low of $0.70 and a 12 month high of $18.36. The company has a market cap of $1.71 million, a PE ratio of 10.03 and a beta of 4.78. The stock’s fifty day moving average is $1.10 and its 200-day moving average is $0.71.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44). The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.11 million. As a group, equities research analysts expect that 60 Degrees Pharmaceuticals will post -3.17 EPS for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.